Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET

Company Participants

Cecilia Jones – Chief Financial Officer

Brian Goff – Chief Executive Officer

Sarah Gheuens – Chief Medical Officer and Head-Research and Development

Tsveta Milanova – Chief Commercial Officer

Conference Call Participants

Gregory Renza – RBC Capital Markets

Tess Romero – JPM

Mark Breidenbach – Oppenheimer

Greg Harrison – Bank of America

Divya Rao – TD Cowen

Operator

Good morning, and welcome to Agios' First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end. Please be advised that this call is being recorded at Agios' request.

I would now like to turn the call over to Agios' Chief Financial Officer, Cecilia Jones. Please go ahead.

Cecilia Jones

Thank you, operator. Good morning, everyone, and welcome to Agios first quarter 2023 conference call. You can access slides for today's call by going to the Investors section of our website, agios.com.

On today's call, I’m joined our Chief Executive Officer, Brian Goff; Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development; and Tsveta Milanova, our Chief Commercial Officer.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.

With that, I will turn the call over to Brian.

Brian Goff

Thanks, Cecilia. Good morning, everyone, and thank you for joining us. Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. We continue to generate consistent and compelling data with our PK activators across multiple disease areas, highlighting the potential of this differentiated mechanism of action to transform patient function, quality of life and long-term outcomes in PK deficiency, thalassemia, sickle cell disease and lower-risk MDS.

Driven by the enthusiasm of our clinical investigators and the operational excellence of our research and development team, I'm pleased to report that we have closed screening in our Phase 3 studies in thalassemia, which together encompass the entire thalassemia population, and expect to complete enrollment of these studies later this month. On behalf of the Agios team, I'd like to thank the patients, caregivers and physicians for their continued participation in these trials.